Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 18;18(6):1295.
doi: 10.3390/ijms18061295.

EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment

Stefanie Keller  1 , Mirko H H Schmidt  2   3   4
Affiliations
Review

EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment

Stefanie Keller et al. Int J Mol Sci. .

Abstract

Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in current concepts of targeted cancer therapy for glioblastoma multiforme (GBM), the most malignant primary brain tumor. The receptors participate in the key processes of tumor cell invasion and tumor-related angiogenesis and their upregulation correlates with the poor prognosis of glioma patients. Glioma cell invasion and increased angiogenesis share mechanisms of the degradation of the extracellular matrix (ECM) through upregulation of ECM-degrading proteases as well as the activation of aberrant signaling pathways. This review describes the role of EGFR and EGFRvIII in those mechanisms which might offer new combined therapeutic approaches targeting EGFR or EGFRvIII together with drug treatments against proteases of the ECM or downstream signaling to increase the inhibitory effects of mono-therapies.

Keywords: EGFR; EGFRvIII; angiogenesis; glioblastoma multiforme; invasion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
EGFR and EGFRvIII contribute to the upregulation of the extracellular matrix (ECM)-degrading proteases matrix metalloproteases (MMPs), urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), and cathepsin B, which leads to degradation of basal membrane components like collagen, laminin, and fibronectin, and facilitate the invasion of tumor cells into the surrounding tissue and blood vessels.
Figure 2
Figure 2
Schematic of signaling pathways activated by EGFR and EGFRvIII and their interaction with integrin and Wnt signaling. Activation upregulates different transcription factors involved in tumor cell proliferation, invasion, and angiogenesis, which can be blocked by various EGFR- and EGFRvIII-specific agents.
See this image and copyright information in PMC

References

    1. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1. - DOI - PubMed
    1. Grossman S.A., Ye X., Piantadosi S., Desideri S., Nabors L.B., Rosenfeld M., Fisher J. Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States. Clin. Cancer Res. 2010;16:2443–2449. doi: 10.1158/1078-0432.CCR-09-3106. - DOI - PMC - PubMed
    1. Scherer H. Structural development in gliomas. Am. J. Cancer. 1938;34:333–351.
    1. Rao J.S. Molecular mechanisms of glioma invasiveness: The role of proteases. Nat. Rev. Cancer. 2003;3:489–501. doi: 10.1038/nrc1121. - DOI - PubMed
    1. Fuller G.N., Bigner S.H. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat. Res. Rev. Genet. Toxicol. 1992;276:299–306. doi: 10.1016/0165-1110(92)90016-3. - DOI - PubMed

MeSH terms

Substances